Hua Er Jie Jian Wen·2025-06-24 01:32Group 1 - The core finding indicates that the experimental drug bimagrumab, when combined with Wegovy, can lead to a weight loss of 22.1% over 48 weeks, with 92.8% of this weight loss coming from fat, compared to a 15.7% weight loss and 71.8% fat loss with Wegovy alone [1] - This combination therapy addresses a significant concern for users, particularly those over 65, regarding muscle loss during rapid weight loss [1][2] - The positive results of the trial validate the forward-looking investment strategy of the company, which acquired bimagrumab for approximately $2 billion from Versanis Bio in 2023 [3] Group 2 - The breakthrough has the potential to reshape the multi-billion dollar weight loss drug market and improve patient treatment experiences and long-term health outcomes [2] - Despite the promising results, there are concerns about the potential for increased side effects with the combination therapy, as indicated by some doctors [3] - A related trial by another company showed similar results but raised concerns when 28% of participants dropped out and two patients died, although a causal relationship with the drug has not been established [3][4]